Back to Search
Start Over
Real-world multi-country study of mutation testing among adult women with HER2-negative advanced breast cancer.
- Source :
- Future Oncology; Apr2022, Vol. 18 Issue 9, p1089-1101, 13p
- Publication Year :
- 2022
-
Abstract
- Aim: We assessed real-world patient demographics and BRCA1/2 mutation testing rates among adult women with HER2-negative advanced breast cancer (ABC). Methods: Oncologists across the USA and in France, Germany, Italy, Spain and the UK provided medical chart data in 2015 and 2017. Results: Overall, 28% of patients received BRCA1/2 mutation testing. Untested patients were more likely to be aged ≥45 years, have hormone receptor-positive/HER2-negative ABC and have no known family history of breast/ovarian cancer. BRCA1/2 mutation testing rates were significantly lower in the European countries, women aged ≥45 years, women without a known family history of breast/ovarian cancer, and women with hormone receptor-positive/HER2-negative ABC versus advanced triple-negative breast cancer. Conclusion:BRCA1/2 mutation testing rates were low, and disparities were observed in patient characteristics among BRCA1/2 mutation-tested versus untested patients. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 14796694
- Volume :
- 18
- Issue :
- 9
- Database :
- Complementary Index
- Journal :
- Future Oncology
- Publication Type :
- Academic Journal
- Accession number :
- 155624281
- Full Text :
- https://doi.org/10.2217/fon-2021-1387